We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.
We are advancing programs in women’s health, including endometriosis-associated pain and egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy.
Over time, we intend to expand our development pipeline to include potential treatments for women's health.
FDA Approved Drugs: ORGOVYX (relugolix 120 mg), MYFEMBREE (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)
Data Provided by Refinitiv. Minimum 15 minutes delayed. Market cap from previous market close.
Annual report which provides a comprehensive overview of the company for the past year
|10-K||EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA|
Quarterly report which provides a continuing view of a company's financial position
|10-Q||EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA|